Fumito Wada
Suita, 5648565, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Rational design of prodrug-type apoB-targeted siRNA for nuclease resistance improvement without compromising gene silencing potency.
Journal: Bioorganic & medicinal chemistry
Published: February 19, 2024
Prodrug-Type Phosphotriester Oligonucleotides with Linear Disulfide Promoieties Responsive to Reducing Environment.
Journal: Chembiochem : a European journal of chemical biology
Published: July 27, 2023
Programmed Instability of Ligand Conjugation Manifold for Efficient Hepatocyte Delivery of Therapeutic Oligonucleotides.
Journal: Nucleic acid therapeutics
Published: September 01, 2021
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides.
Journal: Pharmaceutics
Published: April 04, 2021
Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
Journal: Molecular therapy. Nucleic acids
Published: March 05, 2021
Calcium-Mediated In Vitro Transfection Technique of Oligonucleotides with Broad Chemical Modification Compatibility.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: September 01, 2020
Effect of modular conjugation strategy for N-acetylgalactosamine-targeted antisense oligonucleotides.
Journal: Nucleosides, nucleotides & nucleic acids
Published: October 17, 2019
Effective gene silencing activity of prodrug-type 2'-O-methyldithiomethyl siRNA compared with non-prodrug-type 2'-O-methyl siRNA.
Journal: Bioorganic & medicinal chemistry letters
Published: March 09, 2018
Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Journal: Nucleic acid therapeutics
Published: January 24, 2018
Synthesis, duplex-forming ability, enzymatic stability, and in vitro antisense potency of oligonucleotides including 2'-C,4'-C-ethyleneoxy-bridged thymidine derivatives.
Journal: Organic & biomolecular chemistry
Published: April 26, 2017
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.
Journal: Molecular therapy. Nucleic acids
Published: December 15, 2016
Development of Antisense Drugs for Dyslipidemia.
Journal: Journal of atherosclerosis and thrombosis
Published: July 29, 2016
Last Updated: 09/26/2026